Literature DB >> 8276320

Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer.

E M van Duijnhoven1, F A Lustermans, J W van Wersch.   

Abstract

The coagulation and fibrinolysis profile was evaluated in 40 patients with newly diagnosed untreated colorectal carcinoma (24 males, 16 females; 29 patients without and 11 patients with metastases). Fibrinogen, von Willebrand factor antigen, FVIII:C, thrombin-antithrombin III complex (TAT III), fibrin monomers (FM), plasminogen activator inhibitor-1 (PAI-1) and D-dimers were tested. None of the patients had clinical or laboratory evidence of serious hemorrhage or thrombosis. The results of global routine coagulation tests (aPTT, PT) were not significantly changed. Significant elevations were found for median fibrinogen, von Willebrand factor antigen, FVIII:C, TAT III and D-dimers, compared with a healthy reference group. These results confirm earlier reports of an enhanced level of both coagulation and fibrinolysis markers in carcinoma patients and might be helpful in trying to understand the impact of several relatively new sensitive coagulation and fibrinolysis parameters in colorectal cancer. Moreover the position of the coagulation/fibrinolysis balance might be an explanation for the elevated incidence of thrombotic events in patients with cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8276320     DOI: 10.1159/000216870

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  7 in total

1.  Corticosteroid-responsive Cronkhite-Canada syndrome complicated by thrombosis.

Authors:  Joanna E Sampson; Maureen L Harmon; Mary Cushman; Edward L Krawitt
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

2.  Fibrinolytic activity of earthworms extract (G-90) on lysis of fibrin clots originated from the venous blood of patients with malignant tumors.

Authors:  T M Hrzenjak; M Popović; L Tiska-Rudman
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Authors:  P Jurasz; M W Stewart; A Radomski; F Khadour; M Duszyk; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  Risk of colorectal cancer and clotting factor gene polymorphisms in Moroccan Population.

Authors:  Imane Baghad; Driss Erguibi; Farid Chehab; Sellama Nadifi
Journal:  Int J Adv Res (Indore)       Date:  2017

5.  Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Ewa Sierko; Monika Sobierska; Joanna Kruszewska; Alina Lipska; Piotr Radziwon; Stephanie C Tucker; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  2020-06-24       Impact factor: 3.201

6.  D-Dimer and Carcinoembryonic Antigen Levels: Useful Indicators for Predicting the Tumor Stage and Postoperative Survival.

Authors:  Kemal Tekeşin; Savaş Bayrak; Varol Esatoğlu; Ebru Özdemir; Leyla Özel; Veli Melih Kara
Journal:  Gastroenterol Res Pract       Date:  2016-08-29       Impact factor: 2.260

7.  Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics.

Authors:  Matilda Holm; Mayank Saraswat; Sakari Joenväärä; Ari Ristimäki; Caj Haglund; Risto Renkonen
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.